The independent source for health policy research, polling, and news.
441 - 460 of 1,299 Results
A last-minute agreement among lawmakers restored a provision seeking to hold down rising costs of prescription medicines. Although details on which drugs will be targeted remain sketchy, the legislation would help patients buying insulin and cap Medicare beneficiariesâ out-of-pocket drug costs at $2,000 a year.
Democratic negotiators on Capitol Hill appear to be nearing a compromise on President Joe Bidenâs social spending agenda, spurred partly by Democratic losses on Election Day in Virginia. Meanwhile, the Supreme Court hints it might allow abortion providers to sue Texas over its restrictive new ban. But the relief, if it comes, could be short-lived if the court uses a second case, challenging a law in Mississippi, to weaken or overturn Roe v. Wade. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Mary Ellen McIntire of CQ Roll Call join KHNâs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHNâs Rae Ellen Bichell, who reported and wrote the latest KHN-NPR âBill of the Monthâ feature about an emergency bill for a nonemergency birth.
Reports of waning effectiveness and mixed messages about booster shots fuel the politicization of vaccination.
A federal allocation plan meant to ensure equitable distribution of powerful monoclonal antibody treatments for high-risk patients fails to prioritize nursing home residents, a population that remains particularly vulnerable even after vaccination.
President Joe Biden unveiled a compromise âBuild Back Betterâ framework shortly before taking off for key meetings in Europe, but itâs unclear whether the framework can win the votes of all Democrats in the House and Senate, and it leaves out some of the partyâs health priorities, notably significant provisions to lower prescription drug prices. Meanwhile, younger children may soon be eligible for covid vaccines. Joanne Kenen of Politico and Johns Hopkins, Sarah Karlin-Smith of the Pink Sheet and Rachana Pradhan of KHN join KHNâs Julie Rovner to discuss these issues and more.
With an eye to shutting down Medicare drug price negotiations, drug companies and their lobbying groups gave roughly $1.6 million in the first six months of 2021, with Democrats edging closer than they have in a decade to Republicansâ total haul.
KHN teamed up with Hulu for a discussion of America's opioid crisis, following the Oct. 13 premiere of the online streaming serviceâs new series âDopesick.â
But Americans generally have little confidence that the White House or Congress will recommend the right thing, a new poll shows.
Despite big 2020 campaign promises to deliver lower costs on prescription drugs, Democrats have failed to unite around a legislative plan.
The condition can be an early signal of Alzheimerâs disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Hereâs a collection of their appearances.
At least three promising antiviral treatments for covid-19 are being tested in clinical trials, with results expected as soon as late fall or winter.
Congress is back in session with a short time to finish a long to-do list, including keeping the government operating and paying its bills. Hanging in the balance is President Joe Bidenâs entire domestic agenda, including major changes proposed for Medicare, Medicaid and the Affordable Care Act. Meanwhile, the new Texas abortion law that bans the procedure early in pregnancy is prompting action in Washington. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHNâs Julie Rovner to discuss these issues and more. Also, Rovner interviews former FDA Commissioner Scott Gottlieb about his new book on the covid-19 pandemic.
Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree â but they are cautious about changing the treatment regimen of patients doing well.
The Food and Drug Administration has been mired in controversies related to drug approvals and covid vaccines, all without a permanent leader.
The House oversight committee is requesting conflict-of-interest disclosure forms from a National Academies committee studying organ transplants. KHN previously reported on apparent conflicts among members of a committee studying drug waste.Â
Democrats have hit a snag in their effort to compile a $3.5 trillion social-spending bill this fall â moderates are resisting support for Medicare drug price negotiation provisions that would pay for many of the measureâs health benefit improvements. Meanwhile, the new abortion restrictions in Texas have moved the divisive issue back to the political front burner. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Shefali Luthra of The 19th join KHNâs Julie Rovner to discuss these issues and more. Also this week, Rovner interviewâs KHNâs Phil Galewitz about the latest KHN-NPR âBill of the Monthâ installment, about two similar jaw surgeries with very different price tags.
Despite widespread consensus on the importance of addiction treatment in the ER, many hospitals fail to screen for substance use, offer medications to treat opioid use disorder or connect patients to follow-up care. But some are working to change that.
Governors in Southern states, amid a surge of delta-variant infections, are rushing to provide an experimental antibody cocktail therapy, even as they oppose measures like mask mandates and vaccine passports that health officials say can prevent infection in the first place.
Many experts say the evidence doesnât justify widespread booster shots for adults.
Š 2026 KFF